Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer's disease (AD). Additional secondary and exploratory efficacy analyses and biomarker data including neurofilament light chain (NfL), neurogranin, tau and amyloid are still pending and expected in the coming months.